GENE ONLINE|News &
Viral Defense 2.0: How Long-Acting Biologics and Startups are Reimagining the Flu Season
Across next-generation flu, RSV, and pneumococcal programs, 2026 respiratory trials could redefine seasonal protection and vaccine strategy. Image: Thirdman/pexels
The global respiratory disease vaccine market is entering a period of high-stakes transformation, projected to reach $68.43 billion by the end of 2026 and potentially …
Viral Defense 2.0: How Long-Acting Biologics and Startups are Reimagining the Flu Season Read More »
GO Prime with only $1.49 now
LATEST
Oragenics Submits Annual Report Highlighting Fiscal Year 2025 Financials and Research Updates
2026-03-17
Tempus and Blood Cancer United Collaborate to Build Extensive Pediatric AML Data Registry
2026-03-17
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
